TPST · XBRL financial data

Tempest Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (TPST's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
General and administrative	2,371	3,331*	3,634	3,745	2,994	3,176*	3,309	4,095	3,027	3,538*	5,425	3,431
Operating income (loss)	(6,592)	(7,514)*	(7,974)	(9,582)	(10,551)	(13,918)*	(10,936)	(7,966)	(3,597)	(4,077)*	(27,719)	(5,250)
Interest expense	373	377*	368	372	329	247*	161	46	0	0*	0	0
Other income (expense)	179	403*	438	384	324	352*	237	142	86	56*	23	6
Income tax expense (benefit)	0	0*	0	0	0	0*	0	0	0	0*	0	0
Net income (loss)	(6,786)	(7,488)*	(7,904)	(9,570)	(10,556)	(13,813)*	(10,860)	(7,870)	(3,511)	(4,021)*	(27,696)	(5,244)
Earnings per share, basic USD per share	(0.48)	—	(0.36)	(0.42)	(0.41)	—	(3.16)	(2.07)	(0.79)	—	(2.53)	(0.34)
Earnings per share, diluted USD per share	(0.48)	—	(0.36)	(0.42)	(0.41)	—	(3.16)	(2.07)	(0.79)	—	(2.53)	(0.34)
Weighted average shares, basic thousands of shares	14,122	—	22,234	22,546	25,807	—	3,438	3,803	4,440	4,899*	10,932	15,224
Weighted average shares, diluted thousands of shares	14,122	—	22,234	22,546	25,807	—	3,438	3,803	4,440	4,899*	10,932	15,224

† Share count changed about 1/12 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (TPST's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	11,118	39,230	32,326	31,124	22,116	30,268	21,511	14,280	7,514	7,707	1,805	779
Prepaid and other current assets	1,173	1,133	1,171	424	1,436	1,206	922	823	590	562	641	918
Total current assets	12,291	40,363	33,497	31,548	23,552	31,474	22,433	15,103	8,104	8,269	2,446	1,697
Property and equipment, net	921	840	920	1,014	932	886	817	748	681	605	545	486
Right-of-use asset	10,382	9,952	9,513	9,159	8,904	8,643	8,376	8,104	7,825	7,540	7,248	6,949
Total assets	23,987	51,603	44,378	42,169	33,836	41,488	32,164	24,484	17,129	16,931	10,748	9,633
Accounts payable	1,139	845	1,051	1,357	1,697	2,450	2,187	4,716	922	1,038	585	1,995
Accrued liabilities	1,995	1,673	1,524	2,379	1,459	2,726	4,985	1,221	1,353	937	1,162	715
Current portion of long-term debt	2,134	4,285	6,458	8,645	8,504	6,354	4,190	0	0	0	—	—
Total current liabilities	7,422	9,411	10,691	14,559	13,973	14,220	13,177	7,141	3,525	3,314	3,311	4,450
Long-term debt	8,371	6,264	4,140	2,008	0	0	—	—	—	—	—	—
Lease liability, non-current	9,384	9,160	8,915	8,663	8,406	8,142	7,854	7,560	7,258	6,949	6,615	6,273
Total liabilities	25,177	24,835	23,746	25,230	22,379	22,362	21,031	14,701	10,783	10,263	9,926	10,723
Accumulated deficit	(157,775)	(165,263)	(173,167)	(182,737)	(193,293)	(207,106)	(217,966)	(225,836)	(229,347)	(233,368)	(270,072)	(275,316)
Total stockholders' equity	(1,190)	26,768	20,632	16,939	11,457	19,126	11,133	9,783	6,346	6,668	822	(1,090)
Total liabilities and equity	23,987	51,603	44,378	42,169	33,836	41,488	32,164	24,484	17,129	16,931	10,748	9,633
Common shares outstanding (cover page) thousands of shares	19,247	22,192	22,217	25,208	43,642	45,483	3,682	4,440	4,440	14,344	14,807	15,979

† Share count changed about 1/12 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (TPST's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(6,786)	(7,488)*	(7,904)	(9,570)	(10,556)	(13,813)*	(10,860)	(7,870)	(3,511)	(4,021)*	(27,696)	(5,244)
Net cash from operating activities	(6,487)*	(6,175)*	(7,186)	(5,510)*	(10,182)*	(10,149)*	(8,036)	(8,431)*	(6,779)*	(3,574)*	(7,598)	(2,779)*
Purchases of property and equipment	0*	7*	168	249*	15*	3*	0	0*	0*	0*	0	0*
Net cash from investing activities	0*	(7)*	(168)	(249)*	(15)*	(3)*	0	0*	0*	0*	0	0*
Proceeds from issuing common stock	21*	34,349*	253	4,557*	3,629*	20,152*	1,443	3,570*	0*	1,032*	—	—
Net cash from financing activities	21*	34,349*	450	4,557*	1,541*	17,952*	(721)	1,200*	13*	3,767*	1,696	1,753*
Net change in cash	(6,466)*	—	—	—	—	—	—	—	—	—	—	—

† Share count changed about 1/12 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Tempest Therapeutics	779	not reported	(2,779)*	16.0M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
ProMIS Neurosciences	53,429	not reported	(10,385)*	9.0M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Provectus Biopharmaceuticals	1,157	not reported	(358)*	420.3M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Cumberland Pharmaceuticals	3,862	166	169*	15.0M	—	Q2 FY26 10-QJun 30, 2026
Rockwell Medical	10,519	not reported	2,080*	4.0M	—	Q2 FY26 10-QJun 30, 2026
Champions Oncology	4,358	15,232	(492)	13.9M	8.0 quarters	Q1 FY27 10-QJul 31, 2026
Yarrow Bioscience	22,925	97	(1,992)*	2.7M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Rein Therapeutics	8,542	0	(8,640)*	86.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
OnKure Therapeutics	166,502	not reported	(10,354)*	40.5M	17.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.